QSS
JNCE

Quantitative Systematic Strategies’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Quantitative Systematic Strategies’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,195
Closed -$51K – 701
2018
Q4 		$51K Buy
+15,195
New +$71K 0.01% 651
2018
Q3 		– Sell
-10,622
Closed -$81K – 832
2018
Q2 		$81K Buy
+10,622
New +$153K 0.01% 600

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Quantitative Systematic Strategies's JNCE Position: Q1 2019 in Review

Quantitative Systematic Strategies sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2019, closing a stake of 15,195 shares — an estimated $51K sold.

Quantitative Systematic Strategies first reported a position in JNCE in Q2 2018 and held it in 2 quarters. The position peaked at $81K in Q2 2018. 80 funds tracked by Wall St. Rank hold JNCE as of Q1 2019.

  • Quantitative Systematic Strategies reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 15,195 Jounce Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $51K.
  • Quantitative Systematic Strategies first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Quantitative Systematic Strategies's Jounce Therapeutics, Inc. Common Stock position peaked at $81K in Q2 2018.
  • 80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Quantitative Systematic Strategies's 13F filing for Q1 2019, filed 15 Apr 2019.